Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform trial of lutikizumab for moderate to severe atopic dermatitis
jRCT2061240136Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial in atopic dermatitis (AD) comparing Lutikizumab monotherapy with Placebo to lutikizumab (2 arms). Primary endpoints: Percentage of participants achieving EASI 75 at Week 16 and Percentage of participants who reported adverse events. Started Apr 2025; status: active, not recruiting.
02
Drugs
lutikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2061240136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240136.